Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 15% on Friday . The company traded as high as C$0.23 and last traded at C$0.23. 506,476 shares changed hands during mid-day trading, a decline of 3% from the average session volume of 520,039 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Up 10.0 %
The firm has a market capitalization of C$19.17 million, a price-to-earnings ratio of -11.00 and a beta of 0.20. The business has a 50-day moving average price of C$0.09 and a 200-day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- 3 Stocks to Consider Buying in October
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Breakout Stocks: What They Are and How to Identify Them
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Investing in Construction Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
